Harvard Bioscience (FRA:HBI0) Research & Development: €7.59 Mil (TTM As of Mar. 2026)


FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
48 GF Score
Price €4.08
GF Value €13.30
! 6 Warning Signs
View Full Analysis

What is Harvard Bioscience Research & Development?

Harvard Bioscience FRA:HBI0 48 Research & Development is €7.59 Mil as of Mar. 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 48/100 and a GF Value™ of €13.30. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Harvard Bioscience's Research & Development for the three months ended in Mar. 2026 was €2.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €7.59 Mil.

Harvard Bioscience  (FRA:HBI0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Harvard Bioscience Research & Development Related Terms

Harvard Bioscience Research & Development Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience Research & Development Chart

Harvard Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.56 11.64 10.79 9.94 7.54

Harvard Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.15 1.90 1.82 1.86 2.01
FRA:HBI0
48GF Score
Harvard Bioscience Inc FRA:HBI0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €7.59 Mil mean?
Harvard Bioscience (FRA:HBI0) has a Research & Development of €7.59 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Harvard Bioscience and its competitors.
Is Harvard Bioscience's Research & Development too high?
Harvard Bioscience's current Research & Development is €7.59 Mil. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Research & Development compare to FEMY and RVP?
Harvard Bioscience's Research & Development of €7.59 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current Research & Development is €7.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Research & Development of €7.59 Mil. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current Research & Development is €7.59 Mil. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Research & Development is €7.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.

Key valuation signals for FRA:HBI0:

  • Research & Development: €7.59 Mil
  • GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score

Get the complete analysis for FRA:HBI0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€13.30
GF Value